Search

Your search keyword '"Kim, E.-Y."' showing total 457 results
Start Over Author "Kim, E.-Y."
457 results on '"Kim, E.-Y."'

1. P1069 One-year clinical outcomes of switching to subcutaneous infliximab in patients with inflammatory bowel disease on maintenance of intravenous infliximab therapy with or without remission: A multicentre cohort study

Author

Bae, J H, primary, Park, J B, additional, Baek, J E, additional, Lee, Y J, additional, Kim, K O, additional, Kim, E S, additional, Jo, H H, additional, Hong, S W, additional, Park, S H, additional, Yang, D H, additional, Ye, B D, additional, Byeon, J S, additional, Myung, S J, additional, Yang, S K, additional, Kim, E Y, additional, and Hwang, S W, additional

Published
2024
Full Text
View/download PDF

17. Acute exacerbation of chronic obstructive pulmonary disease in a slaughterhouse.

Author

Kang, W Y, Kim, E Y, Choi, S, and Choi, B S

Subjects
*CHRONIC obstructive pulmonary disease, *DISEASE exacerbation, *ASTHMATICS, *MICROBIOLOGICAL aerosols, *SLAUGHTERING
Abstract

We describe the case of a 52-year-old male who presented with two episodes of acute exacerbations (AE) of chronic obstructive pulmonary disease (COPD) during work, while suspending live chickens for slaughter. The patient was exposed to high levels of bioaerosols, including endotoxins and microorganisms. Endotoxins can induce bronchoconstriction and airway inflammation, and COPD patients are more vulnerable to airway infections caused by microorganisms inhaled with bioaerosols. This study suggests that a high level of bioaerosols may induce airway infections, resulting in acute exacerbations of COPD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium

Author

Verma, S.S. Bergmeijer, T.O. Gong, L. Reny, J.-L. Lewis, J.P. Mitchell, B.D. Alexopoulos, D. Aradi, D. Altman, R.B. Bliden, K. Bradford, Y. Campo, G. Chang, K. Cleator, J.H. Déry, J.-P. Dridi, N.P. Fernandez-Cadenas, I. Fontana, P. Gawaz, M. Geisler, T. Gensini, G.F. Giusti, B. Gurbel, P.A. Hochholzer, W. Holmvang, L. Kim, E.-Y. Kim, H.-S. Marcucci, R. Montaner, J. Backman, J.D. Pakyz, R.E. Roden, D.M. Schaeffeler, E. Schwab, M. Shin, J.G. Siller-Matula, J.M. ten Berg, J.M. Trenk, D. Valgimigli, M. Wallace, J. Wen, M.-S. Kubo, M. Lee, M.T.M. Whaley, R. Winter, S. Klein, T.E. Shuldiner, A.R. Ritchie, M.D. for the ICPC Investigators

Subjects
cardiovascular diseases
Abstract

Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. A genomewide association study (GWAS) was performed using DNA from 2,750 European ancestry individuals, using adenosine diphosphate-induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 (P value = 1.67e−33). After correction for CYP2C19*2 no other single-nucleotide polymorphism reached genomewide significance. GWAS for a combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e−09, 4.53e−08, and 2.60e−10, respectively). CYP2C19*2 is the strongest genetic determinant of on-clopidogrel platelet reactivity. We identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes. © 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Published
2020

39. Aqueous extract of Schizandra chinensis fruit causes endothelium-dependent and -independent relaxation of isolated rat thoracic aorta

Author

Rhyu, M.R., Kim, E.-Y., Yoon, B.-K., Lee, Y.J., and Chen, S.-N.

Subjects
Schisandra -- Health aspects -- Research -- Physiological aspects, Vasodilators -- Physiological aspects -- Research, Blood vessels -- Dilatation, Medicinal plants -- Research -- Health aspects -- Physiological aspects, Biological sciences, Health, Science and technology
Abstract

Abstract An aqueous extract of Schizandra chinensis fruit (ScEx) has long been used to promote the vascular health of postmenopausal women in Korea. This study investigated the ability of ScEx [...]

Published
2006

42. Nitric oxide-mediated vasorelaxation by Rhizoma Ligustici wallichii in isolated rat thoracic aorta

Author

Rhyu, M.-R., Kim, E.-Y., and Kim, B.

Subjects
Nitric oxide -- Health aspects -- Case studies -- Research, Medicinal plants -- Health aspects -- Case studies -- Research, Rats -- Research -- Case studies -- Health aspects, Rattus -- Research -- Case studies -- Health aspects, Biological sciences, Health, Science and technology, Case studies, Research, Health aspects
Abstract

Summary The vasorelaxant effect of Rhizoma Ligustici wallichii and its possible mechanism of action on the vasomotor tone of the rat thoracic aortic rings were examined in an organ bath. [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results